Impact of Regular Low-Frequency Hemoperfusion on Medium- to Long-Term Prognosis in Maintenance Dialysis Patients

Impact of Regular Low-Frequency Hemoperfusion on Medium- to Long-Term Prognosis in Maintenance Dialysis Patients: A Real-World Single-Center Retrospective Study

Objective: To investigate the effect of regular low-frequency hemoperfusion on all-cause mortality and cardiovascular/cerebrovascular mortality risk in maintenance hemodialysis (MHD) patients.

Methods: Data from MHD patients over the past 10 years at our blood purification center were retrospectively collected. Patients were divided into a hemoperfusion group (receiving regular low-frequency hemoperfusion once monthly) and a non-hemoperfusion group. Propensity score matching (PSM) was used to balance baseline characteristics. Differences in cumulative all-cause and cardiovascular/cerebrovascular mortality between the two groups before and after matching were compared. A competing risk model was employed to analyze mortality risk.

Study Overview

• Status: Completed
• Conditions: Retrospective Study; Regular Low-Frequency Hemoperfusion; Medium- to Long-Term Prognosis; Maintenance Dialysis Patients

Detailed Description

Clinical and laboratory data were collected for all enrolled patients. These included age, sex, underlying medical conditions, dialysis vintage, blood pressure, serum albumin, hemoglobin, platelet count, C-reactive protein (CRP), serum calcium, serum phosphorus, intact parathyroid hormone (iPTH), total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, and serum β2-microglobulin. Time-averaged mean values were calculated for blood pressure and laboratory parameters across the entire follow-up period. Data on cardiovascular/cerebrovascular death and all-cause mortality over the past ten years were also compiled.

Given the considerably larger size of the Hemoperfusion Group compared with the Non-Hemoperfusion Group, propensity score matching (PSM) was performed by specialized statisticians during data processing to balance baseline characteristics between the two groups. This approach enabled a systematic assessment of the effect of regular low-frequency hemoperfusion on cardiovascular/cerebrovascular and all-cause mortality in MHD patients.

• Study Type: Observational
• Enrollment (Actual): 879

Contacts and Locations

Study Locations

• China
  • Chongqing Municipality
    • Chongqing, Chongqing Municipality, China, 400016
      • First Affiliated Hospital of Chongqing Medical University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients who received MHD treatment at the Hemodialysis Center of the First Affiliated Hospital of Chongqing Medical University from January 2015 to December 31, 2024. Included patients were aged ≥18 years, received dialysis three times a week (each session lasting 3-4 hours), had basically complete clinical and laboratory records, and were followed up at our center for at least 6 months.

Description

Inclusion criteria:

• Included patients were aged ≥18 years
• Undergo dialysis treatment three times a week (each session lasting 3-4 hours)
• Having basically complete clinical and laboratory records, and having received at least 6 months of follow-up at this center

Exclusion Criteria:

• Under 18 years old
• Does not receive dialysis three times a week (each session lasts 3-4 hours)
• Does not have basic complete clinical and laboratory records, and has not been followed up at this center for at least 6 months

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
hemoperfusion group; receive regular low-frequency hemoperfusion once monthly
non-hemoperfusion group; not receive regular low-frequency hemoperfusion once monthly

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Cardiovascular/Cerebrovascular Death	1, 3, 5, and 10 years
all-cause mortality	1, 3, 5, and 10 years

Collaborators and Investigators

• Sponsor: Yunfeng Xia

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2015
• Primary Completion (Actual): December 31, 2024
• Study Completion (Actual): December 31, 2024

Study Registration Dates

• First Submitted: December 29, 2025
• First Submitted That Met QC Criteria: January 10, 2026
• First Posted (Estimated): January 16, 2026

Study Record Updates

• Last Update Posted (Estimated): January 16, 2026
• Last Update Submitted That Met QC Criteria: January 10, 2026
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Keywords: Hemoperfusion; Survival Analysis; Maintenance Dialysis; Propensity Score Matching; Competing Risk; Cardiovascular/Cerebrovascular Death
• Other Study ID Numbers: Chong qing Medical University

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No